<DOC>
	<DOCNO>NCT02395237</DOCNO>
	<brief_summary>The purpose study ass , single oral administration feed condition , bioequivalence two batch glimepiride/metformin hydrochloride ( HCl ) 2 mg/1000 mg fix dose combination ( FDC ) tablet ( immediate release combination tablet Amaryl® M IR 2/1000 ) manufacture India Turkey .</brief_summary>
	<brief_title>COMPOUND ( INN ) : HOE490O - GLIMEPIRIDE / METFORMIN HCl ( Amaryl® M ) 0 ( Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet ) Fed Conditions Healthy Male and/or Female Subjects .</brief_title>
	<detailed_description>An open-label , randomize , two-treatment crossover bioequivalence study compare two batch fix dose combination Amaryl® M IR 2/1000 ( glimepiride/metformin hydrochloride immediate release combination tablet ) feed condition healthy male and/or female subject . Primary Objective To assess , single oral administration feed condition , bioequivalence two batch glimepiride/metformin hydrochloride ( HCl ) 2 mg/1000 mg fix dose combination ( FDC ) tablet ( immediate release combination tablet Amaryl® M IR 2/1000 ) manufacture India Turkey . Secondary Objective ( ) To assess safety ( include hypoglycemic event ) two FDC ( Amaryl® M IR 2/1000 ) tablet . Up 50 healthy subject enrol 46 subject available final pharmacokinetic evaluation . Study treatment : In period A single dose glimepiride/metformin HCl 2mg/1000 mg FDC ( manufacture India ) Or single dose glimepiride/metformin HCl 2mg/1000 mg FDC ( manufacture Turkey ) administer breakfast . PRIMARY AND SECONDARY ENDPOINT ( S ) Primary Endpoint : Glimepiride metformin : Cmax AUClast Secondary Endpoint ( ) : Glimepiride metformin : AUC0-inf , tlag , tmax t1/2z Safety DURATION OF STUDY ( per patient ) Screening : 15 day Treatments period : 4 day include treatment day Wash-out period : 4 7 day Follow-up : 4 7 day Total study duration : 37 day</detailed_description>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Demography 1 . Male subject female subject nonchildbearing potential ( post menopausal sterilize ) age 18 50 year inclusive . 2 . Body weight 50.0 95.0 kg , inclusive , male , 40.0 85.0 kg , inclusive , female , body mass index 18.0 30.0 kg/m2 , inclusive . Health status 3 . Certified healthy comprehensive clinical assessment ( detailed medical history ( hypo , hypertension , allergy , disease , major surgery , micturition , defecation , sleep , illness within last 3 week prior start trial , registration life style habit ( consumption alcohol , nicotine , coffee , tea , coke , special diet , drug abuse ) complete physical examination ( general state abnormal finding per system : endocrine/metabolic , allergy , drug sensitivity , head , neck , eye , ear , nose , throat , cardiovascular , respiratory , gastrointestinal , hepatic/biliary , urogenital , musculoskeletal , Iymph node , skin , neurological/psychiatric ) . 4 . Normal vital sign 10 minute rest supine position : 90 mmHg &lt; systolic blood pressure ( SBP ) &lt; 140 mmHg 45 mmHg &lt; diastolic blood pressure ( DBP ) &lt; 90 mmHg 40 bpm &lt; heart rate ( HR ) &lt; 100 bpm 5 . Normal standard 12lead electrocardiogram ( ECG ) 10 minute rest supine position follow range ; 120 m &lt; PR &lt; 220 m , QRS &lt; 120 m , QTc≤430 m male , ≤450 m female normal ECG trace unless Investigator considers ECG trace abnormality clinically relevant . 6 . Laboratory parameter within normal range ( define screen threshold Investigator site ) , unless Investigator considers abnormality clinically irrelevant healthy subject ; however blood/serum examination creatinine , alkaline phosphatase , hepatic enzyme ( aspartate aminotransferase , alanine aminotransferase ) , total bilirubin ( unless subject document Gilbert syndrome ) exceed upper laboratory norm . For female nonchildbearing potential , sterilize least 3 month earlier postmenopausal i.e . artificial natural menopause 2 year plasma FSH level &gt; 30 UI/L . Regulations I 07 . Having give write informed consent prior undertake studyrelated procedure . I 08 . Covered health insurance system applicable , and/or compliance recommendation national law force relate biomedical research . I 09 . Not administrative legal supervision . Medical history clinical status E 01 . Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurological , osteomuscular , articular , psychiatric , systemic , ocular , gynecologic ( female ) , infectious disease , sign acute illness . E 02 . Frequent headache and/or migraine , recurrent nausea and/or vomit ( twice month ) . E 03 . Blood donation , volume , within 3 month inclusion . E 04 . Symptomatic hypotension , irrespective decrease blood pressure . E 05 . Presence history drug hypersensitivity , allergic disease diagnose treated physician . E 06 . Major surgery gastrointestinal tract except appendectomy . E 07 . History presence drug alcohol abuse ( alcohol consumption 40 g per day ) . E 08 . Smoking 5 cigarette equivalent per day , unable stop smoking study . E 09 . Excessive consumption beverage contain xanthine base ( Pepsi/cola , tea , coffee ) 4 cup glass per day ) E 10 . If female , pregnancy ( define positive βHCG test ) , breastfeed . Interfering substance E 11 . Medication drug know alter organ system barbiturate , phenothiazine , cimetidine , omeprazole etc . within last 2 month . E 12 . Any medication ( include St John 's Wort ) within 14 day inclusion within 5 time elimination halflife pharmacodynamic halflife medication , vaccination within last 28 day biologics ( antibody derivative ) give within 4 month inclusion . General condition E 13 . Any subject , judgment Investigator , likely noncompliant study , unable cooperate language problem poor mental development . E 14 . Any subject exclusion period previous study accord applicable regulation . E 15 . Any subject contact case emergency . E 16 . Any subject Investigator subinvestigator , research assistant , pharmacist , study coordinator , staff thereof , directly involve conducting study . Biological status E 17 . Positive result follow test : hepatitis B surface ( HBs Ag ) antigen , antihepatitis C virus ( antiHCV ) antibody , antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 anti HIV2 Ab ) . E 18 . Positive result urine drug screen ( amphetamines/methamphetamines , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) . E 19 . Positive alcohol test . Specific study E 20 . Any contraindication glimepiride , accord applicable labeling . E 21 . Any contraindication metformin , accord applicable labeling . E 22 . Use CYP2C9 inhibitor and/or CYP2C9 inducer within 7 day inclusion . E 23 . Vegetarian diet E 24 . Participation another clinical trial time within precede 3 month ( calculated date final examination previous study ) , except previous BE trial case 80 day sufficient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Fed Conditions</keyword>
</DOC>